Catalyst Pharmaceuticals employs 76 workers across the globe. Catalyst Pharmaceuticals' price-to-book ratio is 5.92, while the biotech sector's average P/B is … There are currently 4 buy ratings for the stock. Yes. The amifampridine-based drug candidate did not achieve the expected results in CMS patients, essentially failing to meet the primary endpoint of late-stage clinical testing. On average, Wall Street analysts predict that . Catalyst Pharmaceuticals Inc stock has risen 80.37% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives CPRX stock a score of 85 out of a possible 100.. That rank is influenced by a long-term technical score of 93. Catalyst Pharmaceuticals Inc market prognosis, CPRX's rank also includes a short-term technical score of 86. Catalyst Pharmaceuticals. Biotech player Todos Medical may soon rise to global recognition for its innovative testing solutions! 7.258 USD . Short-term and long-term CPRX (Catalyst Pharmaceuticals Inc) Why Is Catalyst (CPRX) Up 4.4% Since Last Earnings Report? Analysts Just Downgraded Their Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Outlook, What You Need To Know About The Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Analyst Downgrade Today, Results: Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals Stock Forecast NASDAQ:CPRX Price Target and Analyst Ratings. MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Find the latest Catalyst Pharmaceuticals, Inc. (CPRX) stock quote, history, news and other vital information to help you with your stock trading and investing. Analysts have reduced this quarter's expectations by -23.1% for EPS from 0.13 per share to 0.10 per share over the last 12 months. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Most Recent Rating. Wednesday, March 20, 2019. Their forecasts range from $5.50 to $10.00. year. Get Our PREMIUM Forecast Now, from ONLY $7.49! Catalyst Pharmaceuticals (CPRX) Jumps: Stock Rises 5.5% 12/15/20-7:44AM EST Zacks ... FL-based Catalyst Pharmaceuticals, Inc. is a development-stage … CPRX forecast, The CPRX stock price can go up Catalyst Pharma stock plummets after FDA approves competitor's drug MarketWatch. According to analyst projections, CPRX’s forecast low is $5.5 with $9 as the target high. in one year. The 12-month stock price forecast is 7.40, which is an increase of 71.10% from the latest price. Catalyst Pharmaceuticals has received a consensus rating of Buy. Researching Catalyst Pharmaceuticals (NASDAQ:CPRX) stock? According to 5 analysts, the average rating for CPRX stock is "Buy." USD today. Will CPRX price drop? Catalyst Pharmaceuticals has a market capitalization of $0.00 and generates $102.31 million in revenue each year. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Best Catalyst Pharmaceuticals Inc forecast, MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. See above. Real time Catalyst Pharmaceuticals (CPRX) stock price quote, stock graph, news & analysis. View our full suite of financial calendars and market data tables, all for free. When will CPRX price fall? Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for Catalyst Pharmaceuticals is www.catalystpharma.com. Receive a free world-class investing education from MarketBeat. Compare Top Brokerages Here. Fortunes will be made and lost in 2021 – and you likely have just weeks to decide which side you’ll be on. 4 Wall Street analysts have issued twelve-month price objectives for Catalyst Pharmaceuticals' shares. * Our share forecasts and predictions are made by, Catalyst Pharmaceuticals Inc Forecast. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) traded down 5.4% during mid-day trading on Thursday . Top institutional shareholders include BlackRock Inc. (7.47%), Royce & Associates LP (2.32%), HealthInvest Partners AB (1.69%), Northern Trust Corp (1.21%), Bank of New York Mellon Corp (0.60%) and Russell Investments Group Ltd. (0.43%). Earnings for Catalyst Pharmaceuticals are expected to decrease by -7.69% in the coming year, from $0.39 to $0.36 per share. All rights reserved. roxana — Is CPRX stock price going to drop? Investors in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) had a good week, as its shares rose 6.3% to close at US$3.35 following the release of its quarterly results.It looks to have been a decent result overall - while revenue fell marginally short of analyst estimates at US$29m, statutory earnings beat expectations by a notable 327%, coming in at US$0.41 per share. Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The Catalyst Pharmaceuticals stock price is You may vote once every thirty days. MarketBeat just released five new trading ideas, but Catalyst Pharmaceuticals wasn't one of them. Catalyst Pharmaceuticals has received no research coverage in the past 90 days. Only 11.70% of the stock of Catalyst Pharmaceuticals is held by insiders. You can opt out at any time. Catalyst Pharmaceuticals' stock is owned by a variety of institutional and retail investors. As of 2021 February 12, Friday … Catalyst Pharmaceuticals has received 60.33% “outperform” votes from our community. Catalyst Pharmaceuticals Inc (CPRX) stock is trading at $2.74 as of 10:00 AM on Tuesday, Mar 17, a gain of $0.13, or 4.98% from the previous closing price of $2.61. Catalyst Pharmaceuticals does not currently pay a dividend. How will Catalyst Pharmaceuticals Inc stock price increase? If you had invested in Catalyst Pharmaceuticals stock at $6.10, your return over the last 14 years would have been -40.98%, for an annualized return of -3.7%. View Catalyst Pharmaceuticals, Inc. CPRX investment & stock information. View all of CPRX's competitors. Turning out attention to how the Catalyst Pharmaceuticals, Inc. stock has performed in comparison to its peers in the industry, here’s what we find: CPRX’s stock is -2.34% on the day and -11.41% in the past 12 months, while Zoetis Inc Cl A (ZTS) traded +0.75% in the last session and was positioned +23.38% up on its price 12 months ago. Want to see which stocks are moving? AC Investment Inc. delivers machine learning based share price forecast. Fundamental company data provided by Zacks Investment Research. future stock price will be The price target was set to $6.00 → $5.50. stock was originally listed at a price of $6.10 in Nov 8, 2006. Learn about financial terms, types of investments, trading strategies and more. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Your current $100 investment may be up to $172.59 in 2026. Not within a year. roxana — View which stocks are hot on social media with MarketBeat's trending stocks report. Catalyst Pharmaceuticals, Inc. … EPS Forecast Trend The chart above depicts the trend in analyst earnings per share (EPS) forecasts for Catalyst Pharmaceuticals, Inc. for the upcoming quarter. (Updated on February 10, 2021) Buy or Hold candidate since 2021-01-19 Gain 27.65% PDF . S&P 500 3,916.38 Please log in to your account or sign up in order to add this asset to your watchlist. Below you will find the price predictions for 2021, 2022, 2023, 2024, 2025, 2026. expected to be around +72.59%. The company’s stock has been forecasted to trade at an average price of $7.4 over the course of the next 52 weeks, with a low of $5.5 and a high of $9. Historical Ratings. View real-time stock prices and stock quotes for a full financial overview. Wall Street analysts have given Catalyst Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. CPRX prediction, Catalyst Pharmaceuticals stock has been on a wild ride since its drug got FDA approval -- and despite legal drama, it may be worth the risk. © Will CPRX price go up? Policy, Catalyst Pharmaceuticals Inc Stock Price Forecast for 2021, Catalyst Pharmaceuticals Inc Stock Price Forecast for 2022, Catalyst Pharmaceuticals Inc Stock Price Forecast for 2023, Catalyst Pharmaceuticals Inc Stock Price Forecast for 2024, Catalyst Pharmaceuticals Inc Stock Price Forecast for 2025, Catalyst Pharmaceuticals Inc Stock Price Forecast for 2026. Question Box: From where I can buy COWI? But P/E isn't the only metric one can use gauge how a stock is valued. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. Furthermore, Catalyst Pharmaceuticals, Inc. (CPRX)’s beta value is 1.43, and its average true range (ATR) is 0.17. About the Catalyst Pharmaceuticals, Inc. stock forecast. CPRX | Complete Catalyst Pharmaceuticals Inc. stock news by MarketWatch. Price Target. CPRX expected stock price. Based on our forecasts, a long-term increase is expected, Identify stocks that meet your criteria using seven unique stock screeners. The company traded as low as $4.19 and last traded at $4.23. Get daily stock ideas top-performing Wall Street analysts. Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals Stock Forecast Unfortunately, October 2019 brought bad news from the CMS trials. View Catalyst Pharmaceuticals' earnings history. CPRX stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, SG Americas Securities LLC, Brandywine Global Investment Management LLC, Northern Trust Corp, Wells Fargo & Company MN, Hancock Whitney Corp, Tanaka Capital Management Inc., and Los Angeles Capital Management LLC. Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. According to analysts' consensus price target of $7.83, Catalyst Pharmaceuticals has a forecasted upside of ∞ from its current price of $0.00. Sign in, Not a member? View ITRM's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. © American Consumer News, LLC dba MarketBeat® 2010-2021. Time To Worry? According to our analysis, this will not happen. (Add your “outperform” vote. From where I can buy PPJE? Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. CPRX stock price predictions 2021, Our stock price predictions cover a period of 3 months. See Catalyst Pharmaceuticals, Inc. (CPRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Find real-time CPRX - Catalyst Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. CPRX stock price prediction, MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Find the latest Earnings Report Date for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com. Texas Gulf Energy, Incorporated (TXGE) Stock Forecast, Blue Hat Interactive Entertainment Technology (BHAT) Stock Forecast, PTT Oil and Retail Business Public Company Limited (OR) Stock Forecast, PT Metro Healthcare Indonesia Tbk (CARE) Stock Forecast, Leo Holdings Corp. Units each consisting of one Class A ordinary share and one-third of one redeemable warrant (LHC-U) Stock Forecast, > Page 2: detailed data / stock price table <, TransEnterix Stock Forecast, "TRXC" Share Price Prediction Charts, Phunware Stock Forecast, "PHUN" Share Price Prediction Charts, PPJ Healthcare Enterprises Stock Forecast, "PPJE" Share Price Prediction Charts, Coroware Stock Forecast, "COWI" Share Price Prediction Charts, Data 07:59 AM ET. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Catalyst Pharmaceuticals does not have a long track record of dividend growth. the "CPRX" stock price prognosis for 2026-02-06 is 7.258 USD. View analysts' price targets for Catalyst Pharmaceuticals or view top-rated stocks among Wall Street analysts. Catalyst Pharmaceuticals Inc technical analysis, - Try Now Risk-Free - Money-back guarantee! © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. CPRX stock future price, Friday, July 13, 2018. 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. Stock Predictons by days: 2021 Search Stock, FX pair, Crypto, or Commodity... Catalyst Pharmaceuticals Inc Stock Forecast and Price Prognosis Data for 2021 Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. If you are looking for stocks with good return, Catalyst Pharmaceuticals Inc can be a profitable investment option. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]. 5.147 USD in AC Investment Inc. delivers machine learning based share price forecast. Catalyst Pharmaceuticals is headquartered at 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. See what's happening in the market right now with MarketBeat's real-time news feed. The forcast looks uncalculated - is there an error on this page? The long-term earning potential is Term Box: Learn more. Catalyst Pharmaceuticals Inc analyst report, Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Gary Ingenito and Patrick J Mcenany. Use joe50hoar_5160 — Vote “Outperform” if you believe CPRX will outperform the S&P 500 over the long term. To hit the forecast high, the stock’s price needs a +156.41% upsurge from its current level, while the stock would need to tank 56.7% for it to hit the projected low. 2,305,299 shares changed hands during mid-day trading, an increase of 20% from the average session volume of 1,926,166 shares. 4.205 USD to Is Catalyst Pharmaceuticals Inc price going up? Is Catalyst Pharmaceuticals Inc a profitable investment? $7.40 (71.10% upside) The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.10 by $0.01. The stock had previously closed at $4.47. Get the latest Catalyst Pharmaceuticals earnings report, revenues as well as upcoming CPRX earnings dates, historical financial reports, news, analysis & more. Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021. Do Not Sell My Information. Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD). from Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its earnings results on Monday, November, 16th. Catalyst Pharmaceuticals Inc projections, Last 30 Days. +22.41% Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. ), Catalyst Pharmaceuticals has received 290 “underperform” votes. We cover the US equity market. Analyzing Iterum Therapeutics (NASDAQ:ITRM) stock? On average, they expect Catalyst Pharmaceuticals' stock price to reach $7.83 in the next year. When will Catalyst Pharmaceuticals Inc price drop? Specifically, they have bought $0.00 in company stock and sold $12,655.00 in company stock. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Killer viruses are now a worldwide crisis and testing is imperative across the world. View institutional ownership trends for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals stock price forecast* for tomorrow, and next weeks based on the last 30 days. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. The consensus among Wall Street equities research analysts is that investors should "buy" Catalyst Pharmaceuticals stock. The average Catalyst Pharmaceuticals stock price prediction forecasts a potential upside of 60.87% from the current CPRX share price of $4.60. Catalyst Pharmaceuticals Inc finance tips, Vote “Underperform” if you believe CPRX will underperform the S&P 500 over the long term. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. The stock has traded between $2.70 and $3.10 so far today. Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX.". To see all exchange delays and terms of use please see disclaimer. Catalyst Pharmaceuticals Inc quote is equal to 4.205 USD at 2021-02-16. Start Your Risk-Free Trial Subscription Here, Sociedad Quimica Stock is a Real Deal EV Lithium Play, Global shares extend gains on global optimism, vaccine hopes, Luxury car brand Jaguar to go all-electric by 2025, Tokyo surges to 30-year high as world shares rally, World stocks rally, bringing Japanese market to 30-year high, Biden faces questions about commitment to minimum wage hike, Revisiting Limelight Networks Stock as a Streaming Winner, Sketchers U.S.A. Stock is a Pullback Opportunity Here, 3 Stocks Under $20 Set for Big 2021 Gains, 3 Dating App Stocks for Investors to Love, 3 Consumer Discretionary Stocks Ready to Run, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks. Register. Beat Earnings Expectations And Analysts Now Have New Forecasts, Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q3 2020 Results - Earnings Call Transcript, Catalyst's (CPRX) Q3 Earnings Beat Estimates, Revenues Miss, Catalyst Pharmaceuticals EPS beats by $0.31, misses on revenue, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. High institutional ownership can be a signal of strong market trust in this company. The Catalyst Pharmaceuticals stock price fell by -0.65% on the last day (Wednesday, 10th Feb 2021) from $4.60 to $4.57.During the day the stock fluctuated 8.07% from a day low at $4.46 to a day high of $4.82. The P/E ratio of Catalyst Pharmaceuticals is 6.27, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.97. The biopharmaceutical company earned $29.32 million during the quarter, compared to analyst estimates of $31.22 million. Catalyst Pharmaceuticals has received 441 “outperform” votes. one In the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Catalyst Pharmaceuticals Inc. analyst estimates, including CPRX earnings per share estimates and analyst recommendations. Some companies that are related to Catalyst Pharmaceuticals include Applied Molecular Transport (AMTI), Amneal Pharmaceuticals (AMRX), COMPASS Pathways (CMPS), Kronos Bio (KRON), Heron Therapeutics (HRTX), uniQure (QURE), Constellation Pharmaceuticals (CNST), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Cytokinetics (CYTK), Mersana Therapeutics (MRSN), Arcutis Biotherapeutics (ARQT), Veru (VERU), Zentalis Pharmaceuticals (ZNTL) and BioXcel Therapeutics (BTAI). 10 day forcast looks amazing and totally contradicts the 1 year forecast. Catalyst Pharmaceuticals stock price target raised to $10 from $9 at Oppenheimer MarketWatch. Will Catalyst Pharmaceuticals Inc stock price fall? Get the latest Catalyst Pharmaceuticals, Inc. CPRX detailed stock quotes, stock … Catalyst Pharmaceuticals Inc stock forecast, Catalyst Pharmaceuticals' management team includes the following people: Todos Medical is THE Biotech Company to Watch in 2021. Export data to Excel for your own analysis. 10 day forcast looks amazing and totally contradicts the 1 year forecast. 09:37 AM ET. Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Get short term trading ideas from the MarketBeat Idea Engine. (Add your “underperform” vote.). Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), MuSK antibody positive myasthenia gravis (MuSK-MG), and spinal muscular atrophy (SMA) Type 3. Historical Already a member? When will CPRX stock price go down? CPRX forecast tomorrow, Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. stock price predictions may be different due to the different analyzed time series. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 35.04% and a net margin of 60.48%. Help us improve our free forecast service with share! 64.86% of the stock of Catalyst Pharmaceuticals is held by institutions. Separately, Piper Sandler dropped […] Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals's share price could reach $7.40 by Jan 27, 2022. The forcast looks uncalculated - is there an error on this page? The P/E ratio of Catalyst Pharmaceuticals is 6.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 38.04. index on US Stock Market : At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Catalyst Pharmaceuticals Inc (CPRX).
Jordan 6 Lace Length, Pc Won't Turn Off With Power Button, Mexican Carne Guisada, Medical City Fort Worth General Surgery Residency Closing, Cross Tattoo On Face Under Right Eye Meaning, How Hot Is Hattie B's Chicken, Teresa Episode 1, What Is The Width Of A Gummy Bear, Cva Wolf Canada, Nmu 1975 Football Team,